|
|
Volumn 1, Issue 1, 1999, Pages 54-58
|
|
Dose-intensive approaches to ovarian cancer.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE;
ANTINEOPLASTIC AGENT;
CYCLOPHOSPHAMIDE;
DEOXYCYTIDINE;
DRUG DERIVATIVE;
ETOPOSIDE;
GEMCITABINE;
TOPOTECAN;
DOSE RESPONSE;
FEMALE;
HUMAN;
OVARY TUMOR;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PROGNOSIS;
REVIEW;
SURVIVAL;
ANTHRACYCLINES;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
CYCLOPHOSPHAMIDE;
DEOXYCYTIDINE;
DOSE-RESPONSE RELATIONSHIP, DRUG;
ETOPOSIDE;
FEMALE;
HUMANS;
OVARIAN NEOPLASMS;
PROGNOSIS;
SURVIVAL ANALYSIS;
TOPOTECAN;
|
|
EID: 0033187931
PISSN: 15233790
EISSN: None
Source Type: Journal
DOI: 10.1007/s11912-999-0010-x Document Type: Review |
|
Times cited : (3)
|
|
References (42)
|
